KR910001060A - 신규 화합물 - Google Patents

신규 화합물 Download PDF

Info

Publication number
KR910001060A
KR910001060A KR1019900009561A KR900009561A KR910001060A KR 910001060 A KR910001060 A KR 910001060A KR 1019900009561 A KR1019900009561 A KR 1019900009561A KR 900009561 A KR900009561 A KR 900009561A KR 910001060 A KR910001060 A KR 910001060A
Authority
KR
South Korea
Prior art keywords
protein
glycoprotein
recombinant
dna sequence
anchor
Prior art date
Application number
KR1019900009561A
Other languages
English (en)
Other versions
KR0166585B1 (ko
Inventor
볼렁 알렉스
그레고리 디안느
하인더릭크스 미췌
자코브스 포올
마쒜르 마르크
Original Assignee
쟝 스테판느
스미스클라인 바이오로지컬즈(에스.에이.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝 스테판느, 스미스클라인 바이오로지컬즈(에스.에이.) filed Critical 쟝 스테판느
Publication of KR910001060A publication Critical patent/KR910001060A/ko
Application granted granted Critical
Publication of KR0166585B1 publication Critical patent/KR0166585B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrically Driven Valve-Operating Means (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Liquid Crystal (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음.

Description

신규 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (21)

  1. 앵커(anchor)-결핍 gpI. 앵커-결핍 gpII 또는 앵커-결핍 gpIII로 구성되는, 바리셀라-조스터(Varic-clla-Zoster)비루스 당단백질로 부터 얻은 단백질.
  2. 제1항에 있어서, 카르복시 종결 말단에서 완전한 길이 당단백질의 총 아미노산 잔기의 4-20%를 손실한 단백질.
  3. 제2항에 있어서, gpI 1-546, gpII 1-698 및 gpIII 1-802로부터 선택된 단백질.
  4. 제1항에 내지 제3항중 어느 하나에 있어서, 차이니즈 햄스터(Chinese hamster)난소 세포에서 생성된 단백질.
  5. 제1항 내지 제4항에 따른 단백질을 암호화하는 DNA 서열.
  6. 숙주 세포내에서 제5항의 DNA서열을 발현시킬 수 있는 복제성 발현 벡터.
  7. 제5항의 복제성 발현 벡터로 혀일전환된 숙주 세포.
  8. 재조합 곤충세포에서 생성된 VZV 당단백질.
  9. 제8항에 있어서, gp I. gp II. 또는 gp III 인 VZV당단백질.
  10. 제9항에 있어서, 카르복시 말단 앵커 서열이 부족한 VZV 당단백질.
  11. 제10항에 있어서, gpI 1-546, gpII 1-698 및 gpIII 1-802로부터 선택되는 VZV당단백질.
  12. 제8항 내지 제11항에 있어서, 레피도프 테라(Lepidoptera) 세포 또는 드로조필라(Drosophila)세포에서 생성된 단백질.
  13. 곤충 세포내에서 작용하는 조절 인자에 작용가능하게 연결된 제8항 내지 제11항에 따른 VZV당단백질을 암호화하는 DNA 서열을 포함하는 재조합 DNA 분자.
  14. 제13항의 재조합 DNA 분자를 포함하는 재조합 배큐로 비루스(baculo virus).
  15. 제13항 또는 제14항의 재조합 DNA분자 또는 배큐로 비루스를 함유하는 곤충 세포.
  16. 면역보호 양의 제1항 내지 제4항 및 제8항 내지 제12항의 단백질 및 제약학적으로 허용가능한 담체로 구성되는, 바리셀라 및 조스터에 대해 인간을 보호하기 위한 백신.
  17. 백신내에서 사용하기 위한 제1항 내지 제4항 및 제8항 내지 제12항의 단백질.
  18. 백신의 제조를 위한, 제1항 내지 제4항 및 제8항 내지 제12항의 단백질의 이용.
  19. 재조합 숙주 세포내에서 제1항 내지 제4항에 따른 단백질을 암호화하는 DNA 서열을 발현시키고, 단백질 생성물을 회수하는 것으로 구성되는 제1항 내지 제4항에 따른 단백질을 제조하기 위한 방법.
  20. 곤충 세포내에서 제8항 내지 제12항에 따른 단백질을 암호화하는 DNA 서열을 발현시키고, 단백질 생성물을 회수하는 것으로 구성되는 제8항 내지 제12항에 따른 단백질을 제조하기 위한 방법.
  21. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900009561A 1989-06-27 1990-06-27 앵커-결여 vzv 당단백질, 이를 제조하는 방법 및 이의 면역보호적 용도 KR0166585B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37177289A 1989-06-27 1989-06-27
US07371772 1989-06-27
US7/371,772 1989-06-27

Publications (2)

Publication Number Publication Date
KR910001060A true KR910001060A (ko) 1991-01-30
KR0166585B1 KR0166585B1 (ko) 1999-01-15

Family

ID=23465352

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900009561A KR0166585B1 (ko) 1989-06-27 1990-06-27 앵커-결여 vzv 당단백질, 이를 제조하는 방법 및 이의 면역보호적 용도

Country Status (15)

Country Link
EP (1) EP0405867B1 (ko)
JP (1) JPH0349694A (ko)
KR (1) KR0166585B1 (ko)
AT (1) ATE119939T1 (ko)
AU (1) AU625328B2 (ko)
CA (1) CA2019845A1 (ko)
CY (1) CY1933A (ko)
DE (1) DE69017769T2 (ko)
DK (1) DK0405867T3 (ko)
ES (1) ES2071770T3 (ko)
HK (1) HK1006468A1 (ko)
IE (1) IE66516B1 (ko)
NZ (1) NZ234222A (ko)
PT (1) PT94479B (ko)
ZA (1) ZA904915B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068654C (en) 1990-10-04 2011-01-04 Abbas Vafai Varicella-zoster virus antigen
US5824319A (en) * 1990-10-04 1998-10-20 Research Corporation Technologies, Inc. Varicella-zoster virus antigen
DE122006000063I1 (de) * 1992-07-17 2007-05-10 Merck & Co Inc Methode zur Verhinderung von Zoster und Linderung der mit Varicellea verbundenen Postherpetischen Neuralgie
GB9226768D0 (en) * 1992-12-23 1993-02-17 Smithkline Beecham Biolog Vaccines
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
KR970006484A (ko) * 1995-07-27 1997-02-21 수두 바이러스의 당단백질을 대량발현시키는 동물세포주
US7112331B2 (en) 1996-02-09 2006-09-26 Smithkline Beecham Biologicals, S.A. Vaccines against varicella zoster virus gene 63 product
ATE390146T1 (de) * 1996-02-09 2008-04-15 Smithkline Beecham Biolog Vakzine gegen das varicella zostervirus produkt von gen 63
KR100434023B1 (ko) * 1996-02-29 2005-05-09 주식회사 엘지생명과학 수두바이러스의당단백질을대량발현시키는동물세포주
DE19757767A1 (de) 1997-12-23 1999-07-15 Dade Behring Marburg Gmbh Immunreaktive Bereiche des Glycoproteins gpII des Varicella-Zoster-Virus (VZV)
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN110621339A (zh) 2017-04-28 2019-12-27 葛兰素史密丝克莱恩生物有限公司 疫苗接种
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN112142829B (zh) * 2019-06-28 2022-02-22 怡道生物科技(苏州)有限公司 水痘-带状疱疹病毒gE蛋白突变体及其表达方法
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
CN115819616A (zh) * 2021-07-28 2023-03-21 江苏瑞科生物技术股份有限公司 一种基因重组vzv融合蛋白及其制备方法和应用
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
EP0628633B1 (en) * 1984-04-06 2003-01-08 Chiron Corporation Recombinant herpes simplex gB-gD vaccine
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (en) * 1985-08-01 1987-02-25 Merck & Co. Inc. Assay for varicella-zoster virus (VZV) antibodies
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0364492A1 (en) * 1987-06-30 1990-04-25 The Upjohn Company Virus proteins having reduced o-linked glycosylation

Also Published As

Publication number Publication date
CY1933A (en) 1990-06-22
ZA904915B (en) 1991-06-26
AU625328B2 (en) 1992-07-09
ATE119939T1 (de) 1995-04-15
PT94479A (pt) 1991-02-08
PT94479B (pt) 1997-05-28
DE69017769T2 (de) 1995-07-13
EP0405867B1 (en) 1995-03-15
IE902297A1 (en) 1991-01-16
KR0166585B1 (ko) 1999-01-15
AU5779290A (en) 1991-01-03
EP0405867A1 (en) 1991-01-02
ES2071770T3 (es) 1995-07-01
CA2019845A1 (en) 1990-12-27
IE66516B1 (en) 1996-01-10
HK1006468A1 (en) 1999-02-26
DK0405867T3 (da) 1995-05-22
NZ234222A (en) 1992-03-26
JPH0349694A (ja) 1991-03-04
DE69017769D1 (de) 1995-04-20
IE902297L (en) 1990-12-27

Similar Documents

Publication Publication Date Title
KR910001060A (ko) 신규 화합물
KR870009025A (ko) 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 방법, 표현 벡타 및 재조합 숙주 및 그의 재약상 용도
CA2113712A1 (en) Papilloma virus vaccine
KR880700858A (ko) 재조합된 인간의 내피성 세포의 생장인자
CA2155408A1 (en) Compositions containing corneocyte proteins
DE69230993D1 (de) Rekombinante viren vektoren zur expression in muskelzellen
KR920701451A (ko) 인체혈청알부민의 n-말단 단편을 함유하는 융합 단백질
PT102022A (pt) Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
BR9813692A (pt) Processos para aumentar o rendimento de umaproteìna recombinante produzida em cultura decélula de inseto e de pestivìrus recombinante e2ou fragmentos ou proteìna erns do mesmo e paraproduzir hormÈnio estimulante folìculorecombinante, alfa-unidades e/ou beta-unidades, ecomplexos e fragmentos dos mesmos uso de umprocesso, e, vacina.
AU2347997A (en) Synthesis and purification of hepatitis c virus-like particles
EP0210931B1 (en) Vaccine against varicella-zoster virus
KR900014428A (ko) 신규폴리펩타이드 및 그 제조방법
Highlander et al. Oligomer formation of the gB glycoprotein of herpes simplex virus type 1
ES8505253A1 (es) Un procedimiento para preparar un organismo unicelular que tiene una secuencia de adn que codifica un plipeptid0 que tiene un determinante inmunorreactivo u antigeno de una glicoproteina de virus de herpes simplex.
DE3777233D1 (de) Impfstoff gegen varicella-zoster-virus.
EA200000202A1 (ru) Рекомбинантная экспрессия c-пептида инсулина
EP0256677A3 (en) Pseudorabies virus recombinants and their use in the production of proteins
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
RU95113194A (ru) Вакцины, способ получения, применение неинфекционных субвирусных частиц, векторы применение нуклеиновой кислоты
Koteliansky et al. The effect of non-muscle tropomyosin on the interaction of filamin with F-actin
Takehara et al. High level expression of C-terminal truncated recombinant chicken interferon-γ in baculovirus vector system
Caillet-Boudin et al. Functional and structural effects of an Ala to Val mutation in the adenovirus serotype 2 fibre
EP0385394A3 (en) Polyhedrin gene and genetic engineering thereof
WO1988000973A1 (en) Recombinant plasmid dnas, coding for synthesis of polypeptide substances for a vaccine against hepatitis a

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee